Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges. Aspects such as demand for accelerated development timelines, advancing technologies, and the growing issue surrounding sustainability are monopolizing the priorities of bio/pharma companies.
However, through new opportunities it is hoped that greater benefits to patients, particularly those in undertreated populations, will be achieved.
